Sign In
Buy ANIP
$75.23
+0.580 (+0.777%)
At Close: Jun 03, 2026
ANI Pharmaceuticals (ANIP) Expected to Beat Earnings Estimates: Should You Buy?
11:00am, Friday, 01'st May 2026
ANI (ANIP) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is ANI Pharmaceuticals (ANIP) Stock Outpacing Its Medical Peers This Year?
10:43am, Tuesday, 28'th Apr 2026
Here is how ANI Pharmaceuticals (ANIP) and Adlai Nortye Ltd. Sponsored ADR (ANL) have performed compared to their sector so far this year.
NVS SMA Drug Gets CHMP Backing, Malaria Drug Wins WHO Prequalification
01:20pm, Monday, 27'th Apr 2026
Novartis secures CHMP backing for Itvisma in SMA and wins WHO nod for Coartem Baby, targeting critical gaps in rare disease and infant malaria care.
Why ANI (ANIP) is Poised to Beat Earnings Estimates Again
01:11pm, Monday, 27'th Apr 2026
ANI (ANIP) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
09:55am, Monday, 27'th Apr 2026
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Here's Why ANI Pharmaceuticals (ANIP) is a Strong Momentum Stock
10:51am, Friday, 24'th Apr 2026
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
ANI Pharmaceuticals to Discuss First Quarter 2026 Financial Results on May 8, 2026, at 8:00 a.m. ET
06:50am, Friday, 24'th Apr 2026
PRINCETON, N.J., April 24, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that the Company will release its first quarter 2026 financial results
ANIP's Cortrophin Gel Surge Powers 2026 Growth Outlook
11:20am, Monday, 20'th Apr 2026
ANI Pharmaceuticals rides Cortrophin Gel's surge to anchor 2026 growth, with rising guidance and new initiatives positioning the specialty portfolio for continued momentum.
Is ANIP Stock Undervalued at 10x Forward Earnings and $93 Target?
11:20am, Monday, 20'th Apr 2026
ANI Pharmaceuticals trades at 10x forward earnings with a $93 target, but execution in Cortrophin and ophthalmology recovery may decide if the discount closes.
ANI Pharmaceuticals' 2026 Catalysts Include Gout Push and New Generics
11:20am, Monday, 20'th Apr 2026
ANIP eyes 2026 growth via Cortrophin's gout push and steady generics launches, as Rare Disease expansion reshapes priorities and investor focus.
Here's Why ANI Pharmaceuticals (ANIP) is a Strong Growth Stock
10:45am, Monday, 20'th Apr 2026
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
ANI Pharmaceuticals Announces the FDA Approval and Launch of Pimozide Tablets with 180 Day CGT Exclusivity
06:50am, Monday, 20'th Apr 2026
PRINCETON, N.J., April 20, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced the launch of Pimozide Tablets 1 mg and 2 mg. ANI's Pimozide Tablets i
Is ANI (ANIP) a Solid Growth Stock? 3 Reasons to Think "Yes"
01:46pm, Friday, 17'th Apr 2026
ANI (ANIP) is well positioned to outperform the market, as it exhibits above-average growth in financials.
How Much Upside is Left in ANI (ANIP)? Wall Street Analysts Think 41.71%
10:55am, Friday, 17'th Apr 2026
The consensus price target hints at a 41.7% upside potential for ANI (ANIP). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revi
ANI (ANIP) Upgraded to Strong Buy: Here's Why
01:01pm, Thursday, 16'th Apr 2026
ANI (ANIP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
